Goldman Sachs Maintains Buy on Beta Bionics, Raises Price Target to $19

Benzinga Newsdesk www.benzinga.com Positive 77.0%

Neg 0% Neu 0% Pos 77%

Goldman Sachs analyst David Roman maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $17 to $19.